Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia
Table 4
The potential biomarkers and possible metabolite pathways.
m/z
Metabolite
Class
HMDB
VIP
p value
Metabolic pathways
181.1559
1.52
D-Galactose
Carbohydrate
00143
1.5497
<0.001
up
Galactose metabolism
567.3018
2.13
UDP-glucose
00286
1.3043
0.002
up
132.1018
1.94
L-Leucine
amino acid
00687
1.4244
<0.001
up
Aminoacyl-tRNA biosynthesis
182.0809
1.85
L-Tyrosine
00158
1.1778
0.002
up
496.3386
4.16
LysoPC(16:0)
Glycerophospholipid
10382
1.4823
<0.001
up
Glycerophospholipid metabolism
524.3685
5.15
LysoPC(18:0)
10384
1.0618
0.008
up
518.3238
4.79
LysoPC(18:3)
10387
1.5689
0.007
up
466.2898
3.83
LysoPC(14:1)
10380
1.3510
<0.001
up
772.5782
8.97
PC(15:0/20:2)
07946
1.1258
0.004
up
810.6019
9.38
PC(16:0/22:4)
07988
1.0647
0.008
up
676.4853
8.26
PC(14:0/14:1)
07867
1.5373
<0.001
up
684.4608
9.54
PE(14:0/18:4)
08832
1.4224
<0.001
up
712.4935
9.99
PE(14:0/20:4)
08838
1.5114
<0.001
up
699.5945
11.93
DG(22:0/20:5)
glyceride
07607
1.4373
<0.001
up
577.4806
11.03
DG(15:0/18:3)
07076
1.005
0.014
up
302.3058
8.48
Sphinganine
Sphingolipid
00269
1.4622
<0.001
down
Sphingolipid metabolism
371.3699
9.81
Cholest-5-ene
Cholestene
00941
1.3602
<0.001
down
- - -
Note: Data were analyzed by Student’s t-tests. Trend: Case group versus Normal group.
